# A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

> **NCT05044988** · PHASE2 · UNKNOWN · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- HR+/HER2- Advanced and/or Metastatic Breast Cancer

## Interventions

- **DRUG:** HS-10342

## Key facts

- **NCT ID:** NCT05044988
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-30
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05044988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05044988, "A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05044988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*